







**1H 2022**  
**Executive Summary and**  
**General Comments**

**5 August 2022**

Revenue	Profit Before Tax (PBT)	Net Profit <sup>1</sup>	EPS <sup>2</sup>
S\$1,796.1m	S\$212.8m	S\$174.3m	59.8 cents
 25.4% YoY	 31.6% YoY	 24.1% YoY	 24.3% YoY

PBT Margin	Net Profit Margin	NAV/ Share
1H 2022: 11.8%	1H 2022: 9.7%	S\$9.51 <sup>3</sup>
1H 2021: 11.3%	1H 2021: 9.8%	31 Dec 2021: S\$9.35

1. Net Profit refers to Profit attributable to Owners of the Company
2. Earnings per share (EPS) is on a fully diluted basis
3. As at 30 June 2022

## 1H 2022 vs 1H 2021

### Portfolio A


1. Life Science, Genomics, Molecular Diagnostics and Related Materials Technology	Growth
2. Medical Devices and Equipment	Growth
3. Healthcare & Wellness Technology, Lifestyle Consumer Tech, Health Improvement Products and Others	Growth
<b>Overall Portfolio A Performance</b>	<b>Growth</b>

### Portfolio B


4. Instrumentation, Test & Measurement Technology	Growth
5. Networking & Communications, Security & Safety, Building Automation, Industrial IOT	Growth
6. Advanced Payment Systems	Growth
7. Advanced Industrial Technology, Computing & Productivity Systems, Printing & Imaging, Related Components Technology and Others	Growth
<b>Overall Portfolio B Performance</b>	<b>Growth</b>

 Diversified across more than 100 customers

## Revenue (S\$m)



## Net Profit (S\$m)







---

# **FINANCIAL PERFORMANCE REVIEW**

(S\$m)	1H 2022	1H 2021	YoY (%)
<b>Revenue</b>	<b>1,796.1</b>	1,432.2	25.4
<b>Profit Before Tax</b>	<b>212.8</b>	161.7	31.6
<b>PBT Margin (%)</b>	<b>11.8</b>	11.3	-
<b>Income tax expense</b>	<b>(38.3)</b>	(21.3)	79.4
<b>Effective Tax Rate (%)</b>	<b>18.0</b>	13.2	-
<b>Net profit</b>	<b>174.3</b>	140.4	24.1
<b>Net Margin (%)</b>	<b>9.7</b>	9.8	-
<b>EPS (cents)</b>	<b>59.8</b>	48.1	24.3

- Resilient demand from customers across all domains, with the Healthcare & Wellness, Life Science & Genomics and Instrumentation, Test & Measurement technology domains registering strong performance.
- Despite supply chain challenges and cost pressures, profit before tax rose 31.6% to S\$212.8m and PBT margin remained healthy at 11.8%.

(S\$m)	2Q 2022	1Q 2022	2Q 2021	QoQ (%)	YoY (%)
<b>Revenue</b>	906.8	889.3	745.5	2.0	21.6
<b>Profit Before Tax</b>	110.2	102.6	86.7	7.4	27.0
<b>PBT Margin (%)</b>	12.2	11.5	11.6	-	-
<b>Income tax expense</b>	(19.8)	(18.5)	(11.7)	7.4	69.5
<b>Effective Tax Rate (%)</b>	18.0	18.0	13.5	-	-
<b>Net profit</b>	90.2	84.0	75.1	7.4	20.2
<b>Net Margin (%)</b>	10.0	9.5	10.1	-	-
<b>EPS (cents)</b>	31.0	28.8	25.7	7.4	20.5

-  The Group continued to deliver steady sequential performance despite pressures from supply chain challenges, mandated Covid lockdowns in China and an inflationary environment.
-  Venture's differentiating capabilities and continued productivity gains kept PBT margin healthy at 12.2%.




**FINANCIAL  
POSITION AND  
CASH FLOW**



<b>(S\$m)</b>	<b>30 June 2022</b>	<b>31 December 2021</b>
<b>Cash &amp; Bank Balances</b>	<b>704.3</b>	<b>807.9</b>
<b>Net Current Assets</b>	<b>1,884.4</b>	<b>1,830.0</b>
<b>Net Non Current Assets</b>	<b>885.2</b>	<b>889.4</b>
<b>Total Net Assets</b>	<b>2,769.6</b>	<b>2,719.5</b>
<b>Accumulated Profits</b>	<b>1,975.8</b>	<b>1,948.3</b>
<b>Share Capital &amp; Reserves</b>	<b>790.7</b>	<b>768.0</b>
<b>Non-Controlling Interests</b>	<b>3.2</b>	<b>3.1</b>
<b>Total Equity</b>	<b>2,769.6</b>	<b>2,719.5</b>
<b>Net Asset Value per share</b>	<b>S\$9.51</b>	<b>S\$9.35</b>


<b>(S\$m)</b>	<b>30 June 2022</b>	<b>31 December 2021</b>
<b>Trade Receivables</b>	<b>848.2</b>	<b>829.2</b>
<b>Trade Payables</b>	<b>(660.6)</b>	<b>(643.6)</b>
<b>AR- AP</b>	<b>187.6</b>	<b>185.7</b>
<b>Inventories</b>	<b>1,250.4</b>	<b>1,049.4</b>
<b>Working Capital</b>	<b>1,438.0</b>	<b>1,235.1</b>

 In response to continued supply chain constraints, the Group held higher inventories to support customer order fulfillment.



**DECLARED  
INTERIM  
DIVIDEND**

▼ The Board of Directors has declared an interim dividend of **S\$0.25 per share** on a one-tier tax-exempt basis, consistent with the 1H 2021 interim dividend of S\$0.25 per share.



## Key Dates

▼ Book Closure: 5pm, 5 September 2022

▼ Payment: 15 September 2022



# OUTLOOK



For the first half of 2022, Venture recorded 25.4% YoY increase in revenue and 24.1% YoY increase in net profit. Expansion was broad-based across all of its technology domains.

Based on customer/business partnerships' order patterns, Venture expects demand to remain unabated in 2H 2022. The Group sees resilient demand across its diversified customer base, especially in the Life Science & Genomics, Healthcare & Wellness, Networking & Communications, Test & Measurement Instrumentation and Process & Test equipment in the semiconductor technology domains.

The industry continues to see supply lagging behind demand with challenges from global supply chain constraints, rising inflationary pressures and a tight labour situation. Notwithstanding these and other impediments over the next 12 months, with operational excellence and increased focus on inventory management, Venture expects to end the year well.

Looking into the longer-term horizon, the Group will maintain a sharp focus on its business sustainability goals and strategic direction. With planned investments into the expansion of its human capital, development of new differentiating technologies and capabilities, and new manufacturing capacity, Venture will be focusing on execution of its transformational journey to propel the Group's network of Clusters of Excellence to the next level.

This presentation may contain certain forward-looking statements including, but not limited to, statements as to future operating results and plans.

These statements are based on our assumptions and estimates and are subject to known and unknown risks and uncertainties and other factors which may cause the actual results, performance or achievements of the Group to differ materially from any future results, performance or achievements expressed or implied by those projected in the forward-looking statements.

Consequently, readers are cautioned not to place undue reliance on any forward-looking statements.



**Thank You**

**For enquiries, please contact:**

**Judy Tan**

**Investor Relations & Corporate Communications**

**+65 6484 8136**

**[judy.tan-th@venture.com.sg](mailto:judy.tan-th@venture.com.sg)**